Medifast Inc (MED) shareholders
Close on Nov 17, 2026Market cap $136.32MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Renaissance Technologies LLC Joint filing with Renaissance Technologies Holdings Corporation (9.20%) | 1,006,210 | 9.20% | 13G (passive) amendment | Sep 30, 2024 |
| Parsa Kiai Joint filing with Steamboat Capital Partners, LLC (7.10%) | 790,693 | 7.10% | 13D (active) amendment | Aug 20, 2026 |
| Renaissance Technologies Holdings Corporation Joint filing with Renaissance Technologies LLC (6.96%) | 773,710 | 6.96% | 13G (passive) amendment | Jan 2, 2026 |
| Citadel Securities Group LP Joint filing with Citadel Securities GP LLC (6.50%), Kenneth Griffin (6.50%) and 1 more | 715,910 | 6.50% | 13G (passive) | Mar 31, 2026 |
| Susquehanna Fundamental Investments, LLC Joint filing with G1 Execution Services, LLC (6.00%), Susquehanna Securities, LLC (6.00%) | 654,945 | 6.00% | 13G (passive) amendment | Sep 30, 2025 |
| Susquehanna Portfolio Strategies, LLC Joint filing with Susquehanna Securities, LLC (5.30%) | 587,214 | 5.30% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MED | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 778,610 | 6.96% | $8.26M | +4,900 | 0.01% |
| Steamboat Capital Partners, LLC | 706,699 | 6.32% | $7.50M | −891 | 1.60% |
| Two Sigma Investments, LP | 481,381 | 4.30% | $5.11M | +143,223 | 0.00% |
| Vanguard Capital Management LLC | 446,614 | 3.99% | $4.74M | +2,147 | 0.00% |
| Charles Schwab Investment Management Inc | 396,996 | 3.55% | $4.21M | −234,543 | 0.00% |
| BlackRock, Inc. | 369,503 | 3.30% | $3.92M | −574,950 | 0.00% |
| Dimensional Fund Advisors LP | 363,394 | 3.25% | $3.86M | +1,632 | 0.00% |
| American Century Companies Inc | 318,911 | 2.85% | $3.38M | +94,631 | 0.00% |
| Morgan Stanley | 292,508 | 2.62% | $3.10M | −32,804 | 0.00% |
| Goldman Sachs Group Inc | 243,085 | 2.17% | $2.58M | +89,914 | 0.00% |
| Marshall Wace, Llp | 241,649 | 2.16% | $2.56M | New | 0.00% |
| Aqr Capital Management LLC | 236,434 | 2.11% | $2.51M | +90,859 | 0.00% |
| Peapod Lane Capital LLC | 222,576 | 1.99% | $2.36M | +3,513 | 1.59% |
| Lido Advisors, LLC | 220,337 | 1.97% | $2.34M | +37,302 | 0.01% |
| Trexquant Investment LP | 212,684 | 1.90% | $2.26M | +32,603 | 0.01% |
| Jane Street Group, LLC | 164,881 | 1.47% | $1.75M | +38,474 | 0.00% |
| Commons Capital, LLC | 149,916 | 1.34% | $1.59M | +111,916 | 1.11% |
| Quinn Opportunity Partners LLC | 127,112 | 1.14% | $1.35M | – | 0.06% |
| Geode Capital Management, LLC | 121,071 | 1.08% | $1.29M | −132,244 | 0.00% |
| Bridgeway Capital Management, LLC | 117,078 | 1.05% | $1.24M | −40,000 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 113 | 8M | 73.9% | 26 / 43 | 28 / 24 | 2M | 2M |
| Q1 2026 | 112 | 9M | 76.9% | 26 / 33 | 33 / 20 | 2M | 1M |
| Q4 2025 | 109 | 8M | 72.3% | 14 / 24 | 48 / 27 | 1M | 2M |
| Q3 2025 | 123 | 9M | 83.1% | 20 / 43 | 25 / 17 | 1M | 1M |
| Q2 2025 | 120 | 9M | 77.3% | 23 / 45 | 30 / 27 | 1M | 1M |
| Q1 2025 | 124 | 8M | 73.7% | 21 / 37 | 41 / 24 | 1M | 2M |
| Q4 2024 | 129 | 9M | 79.8% | 19 / 35 | 46 / 30 | 1M | 1M |
| Q3 2024 | 140 | 9M | 82.5% | 23 / 29 | 54 / 39 | 2M | 2M |
| Q2 2024 | 158 | 10M | 93.5% | 38 / 51 | 46 / 65 | 4M | 6M |
| Q1 2024 | 186 | 12M | 100.0% | 25 / 61 | 66 / 55 | 3M | 2M |
| Q4 2023 | 216 | 11M | 95.7% | 33 / 76 | 72 / 39 | 2M | 1M |
| Q3 2023 | 223 | 9M | 84.9% | 29 / 72 | 84 / 42 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
137 funds held MED in Q1 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MED | Value | % of fund | As of |
|---|---|---|---|---|---|
| Schwab Fundamental U.S. Small Company ETF | 377,616 | 3.38% | $4.73M | 0.05% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 318,980 | 2.85% | $3.38M | 0.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 232,366 | 2.08% | $2.91M | 0.01% | May 31, 2026 |
| Vanguard Consumer Staples Index Fund | 130,668 | 1.17% | $1.64M | 0.02% | May 31, 2026 |
| iShares U.S. Small-Cap Equity Factor ETF | 120,973 | 1.08% | $1.19M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 115,543 | 1.03% | $1.23M | 0.00% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 110,808 | 0.99% | $1.09M | 0.01% | Jul 31, 2026 |
| Schwab Fundamental U.S. Small Company Index Fund | 67,482 | 0.60% | $663.35K | 0.03% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 66,463 | 0.59% | $832.78K | 0.00% | May 31, 2026 |
| Dimensional US Small Cap Value ETF | 60,623 | 0.54% | $595.92K | 0.01% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 55,568 | 0.50% | $696.27K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 50,935 | 0.46% | $638.22K | 0.00% | May 31, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 48,912 | 0.44% | $518.96K | 0.02% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 44,360 | 0.40% | $436.06K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Fund | 40,900 | 0.37% | $433.95K | 0.44% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nicholas Mark Johnson | President | 13,457 | 0.12% | Mar 27, 2026 |
| Jonathan Barrett MacKenzie | VP, Finance & CAO | 20,838 | 0.19% | Mar 27, 2026 |
| James P. Maloney | Chief Financial Officer | 37,675 | 0.34% | Mar 27, 2026 |
| Parsa Kiai | Director | 32,769 | 0.29% | Nov 6, 2026 |
| Daniel R. Chard | Director | 336,520 | 3.01% | Sep 30, 2026 |
| Jeffrey Matthew Rose | Director | 11,680 | 0.10% | May 28, 2026 |
| Scott Schlackman | Director | 42,229 | 0.38% | May 28, 2026 |
| Ming Xian | Director | – | – | May 28, 2026 |
| Andrea B. Thomas | Director | 35,697 | 0.32% | May 28, 2026 |
| Elizabeth A. Geary | Director | 31,225 | 0.28% | May 28, 2026 |
| Michael A. Hoer | Director | 26,139 | 0.23% | Jun 26, 2025 |
| Jeffrey J. Brown | Director | 33,361 | 0.30% | Jun 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Parsa Kiai Director | Nov 4, 2026 | Buy | +661 | $13.03 | $8.61K | 21,089 |
| Parsa Kiai Director | Oct 28, 2026 | Buy | +158 | $12.24 | $1.93K | 20,428 |
| Parsa Kiai Director | Oct 28, 2026 | Buy | +5,399 | $12.24 | $66.09K | 712,891 |
| Daniel R. Chard Director | Sep 29, 2026 | Sale(10b5-1 plan) | −9,544 | $11.73 | $111.95K | 130,609 |
| Daniel R. Chard Director | Sep 28, 2026 | Sale(10b5-1 plan) | −9,545 | $11.98 | $114.35K | 140,153 |
| Parsa Kiai Director | Aug 26, 2026 | Buy | +1,175 | $12.26 | $14.41K | 20,270 |
| Parsa Kiai Director | Aug 26, 2026 | Buy | +41,975 | $12.26 | $514.61K | 707,492 |
| Parsa Kiai Director | Aug 24, 2026 | Buy | +118 | $12.00 | $1.42K | 19,095 |
| Parsa Kiai Director | Aug 24, 2026 | Buy | +4,211 | $12.00 | $50.53K | 665,517 |
| Parsa Kiai Director | Aug 20, 2026 | Buy | +1,175 | $11.60 | $13.63K | 18,977 |
| Parsa Kiai Director | Aug 20, 2026 | Buy | +41,975 | $11.60 | $486.91K | 661,306 |
| Parsa Kiai Director | Aug 19, 2026 | Buy | +28,538 | $11.66 | $332.75K | 619,331 |
| Parsa Kiai Director | Aug 19, 2026 | Buy | +799 | $11.66 | $9.32K | 17,802 |
| Parsa Kiai Director | May 26, 2026 | Award | +11,680 | – | – | 11,680 |
| Parsa Kiai Director | May 26, 2026 | Award | +7,637 | – | – | 19,317 |
| Jeffrey Matthew Rose Director | May 26, 2026 | Award | +11,680 | – | – | 11,680 |
| Jeffrey Matthew Rose Director | May 26, 2026 | Award | +6,739 | – | – | 18,419 |
| Elizabeth A. Geary Director | May 26, 2026 | Award | +11,680 | – | – | 31,225 |
| Scott Schlackman Director | May 26, 2026 | Award | +11,680 | – | – | 42,229 |
| Andrea B. Thomas Director | May 26, 2026 | Award | +11,680 | – | – | 35,697 |
| Scott Schlackman Director | May 11, 2026 | Buy | +2,500 | $12.53 | $31.33K | 30,549 |
| Scott Schlackman Director | May 8, 2026 | Buy | +2,500 | $12.65 | $31.63K | 28,049 |
| Daniel R. Chard Chairman & CEO, Director | Mar 25, 2026 | Tax withholding | −20,095 | $9.59 | $192.71K | 146,438 |
| Daniel R. Chard Chairman & CEO, Director | Mar 25, 2026 | Award | +36,968 | – | – | 183,406 |
| Daniel R. Chard Chairman & CEO, Director | Mar 25, 2026 | Award | +4,827 | – | – | 188,233 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 25, 2026 | Award | +10,830 | – | – | 20,838 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 25, 2026 | Tax withholding | −862 | $9.59 | $8.27K | 10,008 |
| James P. Maloney Chief Financial Officer | Mar 25, 2026 | Tax withholding | −3,224 | $9.59 | $30.92K | 37,675 |
| James P. Maloney Chief Financial Officer | Mar 25, 2026 | Award | +34,344 | – | – | 72,019 |
| James P. Maloney Chief Financial Officer | Mar 25, 2026 | Award | +1,014 | – | – | 73,033 |
| Daniel R. Chard Chairman & CEO, Director | Mar 20, 2026 | Buy | +17,678 | $10.11 | $178.72K | 17,678 |
| Daniel R. Chard Chairman & CEO, Director | Mar 17, 2026 | Tax withholding | −2,638 | $10.05 | $26.51K | 166,533 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 17, 2026 | Tax withholding | −70 | $10.05 | $704 | 10,870 |
| James P. Maloney Chief Financial Officer | Mar 17, 2026 | Tax withholding | −482 | $10.05 | $4.84K | 40,899 |
| Daniel R. Chard Chairman & CEO, Director | Mar 13, 2026 | Tax withholding | −7,075 | $9.62 | $68.06K | 169,171 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 13, 2026 | Tax withholding | −198 | $9.62 | $1.90K | 10,940 |
| James P. Maloney Chief Financial Officer | Mar 13, 2026 | Tax withholding | −918 | $9.62 | $8.83K | 41,381 |
| Jeffrey J. Brown Director | Jun 25, 2025 | Award | +11,167.54 | – | – | 29,128 |
| Jeffrey J. Brown Director | Jun 25, 2025 | Award | +9,449.46 | $13.39 | $126.53K | 38,578 |
| Michael A. Hoer Director | Jun 25, 2025 | Award | +11,168 | – | – | 26,139 |
| Elizabeth A. Geary Director | Jun 25, 2025 | Award | +11,168 | – | – | 19,545 |
| Andrea B. Thomas Director | Jun 25, 2025 | Award | +11,168 | – | – | 24,017 |
| Scott Schlackman Director | Jun 25, 2025 | Award | +11,168 | – | – | 25,549 |
| Daniel R. Chard Chairman & CEO, Director | Jun 13, 2025 | Buy | +381 | $13.13 | $5.00K | 149,698 |
| James P. Maloney Chief Financial Officer | Mar 25, 2025 | Award | +24,161 | – | – | 42,299 |
| Daniel R. Chard Chairman & CEO, Director | Mar 25, 2025 | Award | +124,953 | – | – | 176,246 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 25, 2025 | Award | +7,671 | – | – | 11,138 |
| James P. Maloney Chief Financial Officer | Mar 17, 2025 | Tax withholding | −438 | $14.35 | $6.29K | 18,138 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 17, 2025 | Tax withholding | −99 | $14.35 | $1.42K | 3,467 |
| Daniel R. Chard Chairman & CEO, Director | Mar 17, 2025 | Tax withholding | −1,864 | $14.35 | $26.75K | 51,293 |
| James P. Maloney Chief Financial Officer | Mar 16, 2025 | Tax withholding | −123 | $13.94 | $1.71K | 18,576 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 16, 2025 | Tax withholding | −60 | $13.94 | $836 | 3,566 |
| Daniel R. Chard Chairman & CEO, Director | Mar 16, 2025 | Tax withholding | −944 | $13.94 | $13.16K | 53,157 |
| James P. Maloney Chief Financial Officer | Mar 13, 2025 | Tax withholding | −835 | $13.87 | $11.58K | 18,699 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Mar 13, 2025 | Tax withholding | −280 | $13.87 | $3.88K | 3,626 |
| Daniel R. Chard Chairman & CEO, Director | Mar 13, 2025 | Tax withholding | −5,001 | $13.87 | $69.36K | 54,101 |
| Daniel R. Chard Chairman & CEO, Director | Dec 3, 2024 | Gift | −149,317.35 | – | – | 0 |
| Daniel R. Chard Chairman & CEO, Director | Dec 3, 2024 | Gift | +149,317.35 | – | – | 149,317 |
| Jonathan Barrett MacKenzie VP, Finance & CAO | Sep 13, 2024 | Tax withholding | −11 | $18.90 | $208 | 3,906 |
| Andrea B. Thomas Director | Jun 20, 2024 | Award | +6,596 | – | – | 12,849 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Medifast's stock actually held short. Settlement fails (shares not delivered on time) peaked at 883,414 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel R. Chard Officer | Sep 29, 2026 | 9,544 | $111.95K | Sep 29, 2026 | Stock Award |
| Daniel R. Chard Officer | Sep 28, 2026 | 9,545 | $114.34K | Sep 28, 2026 | Stock Award |
| Scott Schlackman Director | Mar 8, 2024 | 4,053 | $159.87K | Mar 8, 2024 | Restricted Stock |
| Jeffrey J. Brown Director | Aug 14, 2023 | 38,316 | $3.60M | Aug 14, 2023 | Dividend Reinvestment |
Congress trades
2 trades in Medifast reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Donna Shalala FL27 | Sold | Jun 24, 2019 | $1K–15K | Apr 27, 2020 308 days late |
| Donna Shalala FL27 | Bought | Apr 30, 2019 | $1K–15K | Apr 27, 2020 363 days late |
See a number that looks wrong?